Clinical Report: Combining Fine Needle Aspiration with Single-Cell RNA Sequencing

Overview

This study presents a novel framework combining fine-needle aspiration (FNA) and single-cell RNA sequencing (scRNA-seq) to investigate metabolic dysfunction-associated steatotic liver disease (MASLD).

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease, affecting a significant portion of the adult population. Understanding the immune response in MASLD is crucial as it plays a central role in disease progression. Traditional research methods often require extensive animal use and large tissue samples.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• The FNA-scRNA-seq framework enables high-precision longitudinal sampling of liver tissue.
• This method allows for the profiling of both innate and adaptive immune cells during MASH progression.
• Dynamic shifts in the hepatic immune landscape were observed following dietary interventions.
• The study supports the feasibility of using FNA as a less invasive alternative to traditional biopsy methods in animal studies.

Clinical Implications

The integration of FNA and scRNA-seq may provide a more efficient approach to studying liver diseases like MASLD.

Conclusion

The findings demonstrate the potential of the FNA-scRNA-seq framework as a valuable tool for longitudinal immune profiling in MASLD research.

Related Resources & Content

1. Frontiers in Medicine, 2026 -- Integrating single-cell RNA-seq and machine learning to dissect polyamine metabolism in metabolic dysfunction-associated steatotic liver disease
2. npj Digital Medicine, 2026 -- Combining Multi-Omics Approaches with Machine Learning to Unravel Cellular Diversity and Fibrotic Regulatory Pathways in the Transition from MASLD to MASH
3. Journal of Gastroenterology, 2025 -- Intracellular Organelle Abnormalities in Metabolic Dysfunction-Associated Steatotic Liver Disease
4. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Utilizing Machine Learning for the Discovery of Biomarkers Aiding in the Early Detection of Metabolic Dysfunction–Associated Steatotic Liver Disease
5. Clinical care pathway for the risk stratification and management of patients with MASLD, American Gastroenterological Association -- 2026
6. Notable Approvals | Drugs | FDA
7. Diagnostic Performance of Non-invasive Tests for Hepatic Fibrosis Using Liver Biopsy As the Reference Standard: A Systematic Review and Meta-Analysis - PubMed
8. Clinical care pathway for the risk stratification and management of patients with MASLD  - American Gastroenterological Association